Direct-acting antiviral medications cure hepatitis C infection in the vast majority of treated patients within a course lasting typically eight to twelve weeks, a genuinely transformative advance over the older interferon-based regimens with far lower cure rates and considerably worse side effect profiles. Despite this, national and global hepatitis C elimination targets remain off track, and the reasons trace to access barriers rather than any remaining scientific limitation in the treatment itself.
The "Cascade of Care" Has Multiple Points Where Patients Fall Off
Public health researchers describe hepatitis C management as a cascade with several sequential steps — screening, diagnosis confirmation, linkage to care, treatment initiation, and cure confirmation — and elimination progress depends on patients successfully passing through every stage, not just the treatment step itself. Studies tracking this cascade have found substantial drop-off at multiple points, meaning even a curative treatment with excellent efficacy has limited population-level impact if patients are not being screened, diagnosed, and connected to a prescriber in the first place.
Universal Screening Recommendations Have Not Fully Translated Into Practice
Current guidelines recommend at least one-time hepatitis C screening for all adults, a shift from earlier risk-factor-based screening approaches that missed a substantial share of infected individuals who did not report recognized risk factors — but actual screening implementation in routine primary care remains inconsistent, and many adults who would benefit from universal screening under current guidelines have never actually been tested.
Insurance Prior Authorization Requirements Have Historically Delayed Treatment
Despite direct-acting antivirals having curative efficacy regardless of disease stage, some state Medicaid programs and commercial payers historically imposed restrictions limiting treatment access to patients with more advanced liver disease, or requiring documented sobriety periods before approving treatment — restrictions not supported by clinical evidence, since treating hepatitis C early prevents disease progression rather than only reversing damage already done. Advocacy and litigation have reduced some of these restrictions over time, though prior authorization friction remains a documented barrier in various forms across different payers.
Substance Use and Housing Instability Complicate the Care Cascade
A meaningful share of new hepatitis C infections occur among people who inject drugs, a population that faces additional, distinct barriers to completing the full care cascade, including housing instability, stigma within healthcare settings, and competing survival priorities that can make consistent medical follow-up genuinely difficult regardless of how effective the treatment itself is. Programs that integrate hepatitis C testing and treatment directly into substance use treatment settings and syringe service programs have shown improved cascade completion compared to referring patients out to a separate, disconnected care setting.
Reinfection Risk Requires an Ongoing Prevention Strategy, Not Just Cure
Curing hepatitis C does not confer immunity against future infection, meaning patients with ongoing risk factors, particularly continued injection drug use, can become reinfected after a successful cure — this reality has shaped harm reduction approaches that treat hepatitis C cure and prevention as complementary rather than treating a completed cure as the endpoint of the clinical relationship.
Conclusion
Hepatitis C elimination remains achievable given the treatment's genuine curative efficacy, but progress depends on closing screening, access, and care-cascade completion gaps rather than any remaining limitation in the medication itself. Facilities expanding hepatitis C screening and treatment programs depend on reliable lab supplies to support the testing infrastructure this cascade requires.
